The DOI matches its Crossref record; 117 of the 119 references it cites were found in a registry or an index.
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Open accessAbstract
Currently available evidence strongly supports the position that the initiating event in Alzheimer's disease (AD) is related to abnormal processing of beta-amyloid (Abeta) peptide, ultimately leading to formation of Abeta plaques in the brain. This process occurs while individuals are still cognitively normal. Biomarkers of brain beta-amyloidosis are reductions in CSF Abeta(42) and increased amyloid PET tracer retention. After a lag period, which varies from patient to patient, neuronal dysfunction and neurodegeneration become the dominant pathological processes. Biomarkers of neuronal injury and neurodegeneration are increased CSF tau and structural MRI measures of cerebral atrophy. Neurodegeneration is accompanied by synaptic dysfunction, which is indicated by decreased fluorodeoxyglucose uptake on PET. We propose a model that relates disease stage to AD biomarkers in which Abeta biomarkers become abnormal first, before neurodegenerative biomarkers and cognitive symptoms, and neurodegenerative biomarkers become abnormal later, and correlate with clinical symptom severity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Studies of non-demented elderly cohorts overall report approximately 20–40% are PIB-positive [67, 68, 71–78].”
From Brain aging, Alzheimer's disease, and mitochondria (2011) · cites this paper as [76]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These investigations have established that volumetric decline occurs initially in medial temporal lobe grey matter, following tau protein deposition, and is closely correlated to cognitive decline.”
From White matter microstructural abnormality precedes cortical volumetric decline in Alzheimer’s disease: evidence from data-driven disease progression modelling (2022) · cites this paper as Jack Jr. et al 2010
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“On the regional level, abnormality is evident in medial temporal lobe areas first (hippocampus and entorhinal cortex), then in lateral temporal lobe areas (mid-temporal gyrus and fusiform gyrus) and finally in frontal lobe areas (Jack Jr. et al 2010, Young et al 2014).”
From White matter microstructural abnormality precedes cortical volumetric decline in Alzheimer’s disease: evidence from data-driven disease progression modelling (2022) · cites this paper as Jack Jr. et al 2010
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“because measures of all biomarkers studied to date have considerable overlap with those found other types of dementia (as well the cognitively normal elderly population), it remains difficult to determine whether or not cognitive impairment is due to AD or another more dominant and concurrent process.”
From Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010 (2012) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“it is Tau pathology and synapse loss that temporally correlate with cognitive impairment and precede overt neurodegeneration (Jack et al., 2010; Scheff et al., 2006; Spires-Jones and Hyman, 2014”
From Changes in the Synaptic Proteome in Tauopathy and Rescue of Tau-Induced Synapse Loss by C1q Antibodies (2018) · cites this paper as Jack et al., 2010
Experimental — accuracy not yet measured
The cited source says what the claim attributes to it.
In the citing paper
“Amyloid accumulation probably starts many years before the onset of symptoms,2,26,27 and initiation of anti-amyloid treatment only after dementia develops may be too late to affect the clinical course of the disease.28”
From Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease (2014) · cites this paper as [26]
The cited source says what the claim attributes to it.
In the citing paper
“Firstly, cognitive decline is more closely correlated to neurodegeneration than tau accumulation (Jack Jr. et al 2010).”
From White matter microstructural abnormality precedes cortical volumetric decline in Alzheimer’s disease: evidence from data-driven disease progression modelling (2022) · cites this paper as Jack Jr. et al 2010
The cited source says what the claim attributes to it.
In the citing paper
“Alzheimer’s disease (AD) is characterized by deposition of hallmark pathological peptides and neurodegeneration that progress across partially overlapping neuroanatomical and temporal axes1,2.”
From Integrated multimodal cell atlas of Alzheimer’s disease (2024) · cites this paper as [2]
In the citing paper
“Autosomal dominant mutations to the MAPT (tau) gene lead to neuronal tangle pathology and frontotemporal dementia but not to amyloid plaques 122,123 , suggesting that tau pathology does not induce Aβ pathology.”
From The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics (2022) · cites this paper as [123]
In the citing paper
“Amyloid plaques appear a decade or two before clinical symptoms of AD, but it is tau pathology and synapse loss that correlate best with cognitive impairment during disease progression (Jack et al., 2010).”
From Microglia in Alzheimer’s disease (2018) · cites this paper as Jack et al., 2010
In the citing paper
“Extensive biomarker and imaging studies indicate that amyloid-β aggregation is the earliest pathological event in Alzheimer’s disease, followed at a later stage by pathological changes of tau aggregation extending beyond the limbic system to the neocortex, which correlates with brain atrophy and cognitive decline2,3.”
From Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight (2018) · cites this paper as [2]
In the citing paper
“Their timeline states that in individuals who develop AD, Aβ plaque deposition and reduced CSF Aβ occur first. Next, CSF tau levels rise. These changes manifest years before clinical signs or symptoms develop. Later on hippocampal atrophy appears, followed shortly thereafter by memory decline and eventually dementia. Full progression from Aβ changes to clinical decline takes approximately 10 to 20”
From The Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives (2014) · cites this paper as [205]
In the citing paper
“Plaque formation rates also vary over time [217]. After a period of rapid accumulation, plaque deposition gradually slows and by the time symptoms manifest plaque deposition is essentially done [20, 205, 218].”
From The Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives (2014) · cites this paper as [205]
In the citing paper
“data argue symptoms generally manifest only after plaques stop forming (Figure 5) [205, 216, 217].”
From The Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives (2014) · cites this paper as [205]
In the citing paper
“As people meeting preclinical AD criteria may remain cognitively stable for many years [205, 214], these trials will take a long time to complete.”
From The Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives (2014) · cites this paper as [205]
In the citing paper
“The new AD biological framework and the model of pathologic AD biomarkers from Jack and colleagues 18 conceptualize a progressive sequence of measurable biochemical, neurophysiological, and neuroanatomical alterations that can be detected years before psychometrically and clinically noticeable deterioration in cognition, behavior, and function.”
From The Alzheimer’s Disease Clinical Spectrum (2019) · cites this paper as [18]
In the citing paper
“The neuropathological changes that are quintessential for AD diagnosis—namely, the development of amyloid plaques and tau tangles—are considered to develop years before onset of the cognitive changes that characterize AD dementia [26].”
From Deep proteomic network analysis of Alzheimer’s disease brain reveals alterations in RNA binding proteins and RNA splicing associated with disease (2018) · cites this paper as [26]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429
Mild cognitive impairment as a diagnostic entity
Petersen, R. C. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01388.x · Cited by 7,864
Self-citationImaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411
Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397
Interplay between Cortical Spreading Depolarization and Seizures
Kramer, D. R., Fujii, T., Ohiorhenuan, I. E., & Liu, C. Y. (2017) · Stereotactic and Functional Neurosurgery · doi:10.1159/000452841 · Cited by 3,721
Cited by
Sorted by citations
Items 501–600 of 1,077
Prediction of Dementia in Primary Care Patients
Jessen, F., Wiese, B., Bickel, H., Eifflaender‐Gorfer, S., Fuchs, Â., Kaduszkiewicz, H., Köhler, M., Luck, T., Mösch, E., Pentzek, M., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016852 · Cited by 147
Kester, M. I., Teunissen, C. E., Sutphen, C., Herries, E. M., Ladenson, J. H., Xiong, C., Scheltens, P., van der Flier, W. M., Morris, J. C., Holtzman, D. M., et al. (2015) · Alzheimer's Research & Therapy · doi:10.1186/s13195-015-0142-1 · Cited by 146
Li, W., Yu, J., Liu, Y., Huang, X., Abumaria, N., Zhu, Y., Huang, X., Xiong, W., Ren, C., Liu, X.-G., et al. (2014) · Molecular Brain · doi:10.1186/s13041-014-0065-y · Cited by 146
Peters, D. G., Connor, J. R., & Meadowcroft, M. D. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.08.007 · Cited by 147
Increased brain atrophy rates in cognitively normal older adults with low cerebrospinal fluid Aβ1‐42
Schott, J. M., Bartlett, J. W., Fox, N. C., Barnes, J., & Initiative, A. D. N. (2010) · Annals of Neurology · doi:10.1002/ana.22315 · Cited by 146
Remote Blood Biomarkers of Longitudinal Cognitive Outcomes in a Population Study
Rajan, K. B., Aggarwal, N. T., McAninch, E. A., Weuve, J., Barnes, L. L., Wilson, R. S., DeCarli, C. S., & Evans, D. A. (2020) · Annals of Neurology · doi:10.1002/ana.25874 · Cited by 146
Copper Toxicity Links to Pathogenesis of Alzheimer’s Disease and Therapeutics Approaches
Ijaz, H. W., Wang, W., & Lang, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207660 · Cited by 146
Tauvid™: The First FDA-Approved PET Tracer for Imaging Tau Pathology in Alzheimer’s Disease
Jie, C. V. M. L., Treyer, V., Schibli, R., & Mu, L. (2021) · Pharmaceuticals · doi:10.3390/ph14020110 · Cited by 146
Shapes of the Trajectories of 5 Major Biomarkers of Alzheimer Disease
Jack, C. R., Vemuri, P., Wiste, H. J., Weigand, S. D., Lesnick, T. G., Lowe, V., Kantarci, K., Bernstein, M. A., Senjem, M. L., Gunter, J. L., et al. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.3405 · Cited by 145
Self-citationAbsence of practice effects in preclinical Alzheimer’s disease.
Hassenstab, J. J., Ruvolo, D., Jasielec, M. S., Xiong, C., Grant, E., & Morris, J. C. (2015) · Neuropsychology · doi:10.1037/neu0000208 · Cited by 145
Mitochondrial Dysfunction and Immune Activation are Detectable in Early Alzheimer's Disease Blood
Lunnon, K., Ibrahim, Z. M., Proitsi, P., Lourdusamy, A., Newhouse, S., Sattlecker, M., Furney, S. J., Saleem, M., Soininen, H. S., Kłoszewska, I., et al. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-111592 · Cited by 145
Lorenzi, M., Filippone, M., Frisoni, G. B., Alexander, D. C., & Sebastien Ourselin, A. (2017) · NeuroImage · doi:10.1016/j.neuroimage.2017.08.059 · Cited by 145
Contemplating Alzheimer’s Disease and the Contribution of White Matter Hyperintensities
Brickman, A. M. (2013) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-013-0415-7 · Cited by 144
Yuki, D., Sugiura, Y., Zaima, N., Akatsu, H., Takei, S., Yao, I., Maesako, M., Kinoshita, A., Yamamoto, T., Kon, R., et al. (2014) · Scientific Reports · doi:10.1038/srep07130 · Cited by 144
Da, X., Toledo, J. B., Zee, J., Wolk, D. A., Xie, S. X., Ou, Y., Shacklett, A., Parmpi, P., Shaw, L. M. J., Trojanowski, J. Q., et al. (2013) · NeuroImage Clinical · doi:10.1016/j.nicl.2013.11.010 · Cited by 144
Self-citationDavis, D. H. J., Skelly, D., Murray, C., Hennessy, E., Bowen, J. S. T., Norton, S., Brayne, C., Rahkonen, T., Sulkava, R. O., Sanderson, D. J., et al. (2014) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2014.08.005 · Cited by 144
3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects
Apostolova, L. G., Hwang, K., Andrawis, J. P., Green, A. E., Babakchanian, S., Morra, J. H., Cummings, J. L., Toga, A. W., Trojanowski, J. Q., Shaw, L. M. J., et al. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.05.003 · Cited by 144
Self-citationOral Microbiota and Alzheimer’s Disease: Do All Roads Lead to Rome?
Sureda, A., Daglia, M., Argüelles Castilla, S., Sanadgol, N., Fazel Nabavi, S., Khan, H., Belwal, T., Jeandet, P., Marchese, A., Pistollato, F., et al. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2019.104582 · Cited by 143
Preclinical AD predicts decline in memory and executive functions in subjective complaints
van Harten, A. C., Smits, L. L., Teunissen, C. E., Visser, P. J., Koene, T., Blankenstein, M. A., Scheltens, P., & van der Flier, W. M. (2013) · Neurology · doi:10.1212/wnl.0b013e3182a8418b · Cited by 143
New landscape of the diagnosis of Alzheimer’s disease
Frisoni, G. B., Hansson, O., Nichols, E., Garibotto, V., Schindler, S. E., van der Flier, W. M., Jessen, F., Villain, N., Arenaza-Urquijo, E. M., Crivelli, L., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01294-2 · Cited by 143
Self-citationObjective subtle cognitive difficulties predict future amyloid accumulation and neurodegeneration
Thomas, K. R., Bangen, K. J., Weigand, A. J., Edmonds, E. C., Wong, C. G., Cooper, S., Delano‐Wood, L., Bondi, M. W., & Initiative, A. D. N. (2019) · Neurology · doi:10.1212/wnl.0000000000008838 · Cited by 144
Mosconi, L., Murray, J., Tsui, W. H., Li, Y., Davies, M., Williams, S., Pirraglia, E., Spector, N. C., Osorio, R. S., Glodzik, L., et al. (2014) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2014.17 · Cited by 143
Mild cognitive impairment with suspected nonamyloid pathology (SNAP): Prediction of progression
Caroli, A., Prestia, A., Galluzzi, S., Ferrari, C., van der Flier, W. M., Ossenkoppele, R., Van Berckel, B., Barkhof, F., Teunissen, C., Wall, A. E., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001209 · Cited by 142
Self-citationMulticellular communities are perturbed in the aging human brain and Alzheimer’s disease
Cain, A., Taga, M., McCabe, C., Green, G. S., Hekselman, I., White, C. C., Lee, D. I., Gaur, P., Rozenblatt-Rosen, O., Zhang, F., et al. (2023) · Nature Neuroscience · doi:10.1038/s41593-023-01356-x · Cited by 142
Association of APOE with tau-tangle pathology with and without β-amyloid
Farfel, J. M., Yu, L., Jager, P. L. D., Schneider, J. A., & Bennett, D. A. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.09.011 · Cited by 142
Rönnlund, M., Sundström, A., Adolfsson, R., & Nilsson, L. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.11.006 · Cited by 142
Hampel, H. J., Lista, S., & Khachaturian, Z. S. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.05.2116 · Cited by 142
Hellwig, K., Kvartsberg, H., Portelius, E., Andréasson, U., Oberstein, T. J., Lewczuk, P., Blennow, K., Kornhuber, J., Maler, J. M., Zetterberg, H., et al. (2015) · Alzheimer s Research & Therapy · doi:10.1186/s13195-015-0161-y · Cited by 144
Leandrou, S., Petroudi, S., Kyriacou, P. A., Reyes‐Aldasoro, C. C., & Pattichis, C. S. (2018) · IEEE Reviews in Biomedical Engineering · doi:10.1109/rbme.2018.2796598 · Cited by 142
Blackman, J., Swirski, M., Clynes, J., Harding, S., Leng, Y., & Coulthard, E. (2021) · Journal of Sleep Research · doi:10.1111/jsr.13229 · Cited by 141
Tau pathology in neurodegenerative disease: disease mechanisms and therapeutic avenues
Samudra, N. P., Lane‐Donovan, C., VandeVrede, L. A., & Boxer, A. L. (2023) · Journal of Clinical Investigation · doi:10.1172/jci168553 · Cited by 142
Cerebrospinal Fluid Level of YKL-40 Protein in Preclinical and Prodromal Alzheimer's Disease
Antonell, A., Mansilla, A., Rami, L., Lladó, A., Iranzo, Á., Olives, J., Balasa, M., Sánchez‐Valle, R., & Molinuevo, J. L. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-140624 · Cited by 141
Biomarkers for Alzheimer's disease therapeutic trials
Hampel, H. J., Wilcock, G. K., Andrieu, S., Aisen, P. S. S., Blennow, K., Broich, K., Carrillo, M. C., Fox, N. C., Frisoni, G. B., Isaac, M., et al. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.11.005 · Cited by 140
Self-citationHarkins, K. A., Sankar, P. L., Sperling, R. A., Grill, J. D., Green, R. C., Johnson, K. A., Healy, M. E., & Karlawish, J. H. (2015) · Alzheimer s Research & Therapy · doi:10.1186/s13195-015-0112-7 · Cited by 140
Dementia risk and prevention by targeting modifiable vascular risk factors
Tariq, S., & Barber, P. A. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.14132 · Cited by 140
Ito, K., Corrigan, B., Zhao, Q., French, J. L., Miller, R., Soares, H. D., Katz, E., Nicholas, T., Billing, B., Anziano, R., et al. (2010) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2010.03.018 · Cited by 140
Gene-Environment Interactions: Lifetime Cognitive Activity, APOE Genotype, and Beta-Amyloid Burden
Wirth, M., Villeneuve, S., Joie, R. L., Marks, S. M., & Jagust, W. J. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.4612-13.2014 · Cited by 139
Self-citationBrain imaging in the study of Alzheimer's disease
Reiman, E. M., & Jagust, W. J. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2011.11.075 · Cited by 139
Self-citationAssociations between amyloid β and white matter hyperintensities: A systematic review
Roseborough, A. D., Ramirez, J., Black, S. E., & Edwards, J. D. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2017.01.026 · Cited by 139
Rueda, A. D., Lau, K. M., Saito, N. H., Harvey, D. J., Risacher, S. L., Aisen, P. S. S., Petersen, R. C., Saykin, A. J., Farias, S. T., & Initiative, A. D. N. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.09.002 · Cited by 138
Self-citationComparison of Pittsburgh compound B and florbetapir in cross‐sectional and longitudinal studies
Su, Y., Flores, S. E., Wang, G., Hornbeck, R. C., Speidel, B. A., Joseph‐Mathurin, N., Vlassenko, A. G., Gordon, B. A., Koeppe, R. A., Klunk, W. E., et al. (2019) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2018.12.008 · Cited by 138
Self-citationIs Alzheimer’s a disease of the white matter?
Sachdev, P. S., Zhuang, L., Braidy, N., & Wen, W. (2013) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e32835ed6e8 · Cited by 137
Novel plasma biomarker surrogating cerebral amyloid deposition
KANEKO, N., Nakamura, A., Washimi, Y., Kato, T., Sakurai, T., Arahata, Y., Bundo, M., Takeda, A., Niida, S., Ito, K., et al. (2014) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.90.353 · Cited by 138
Wirth, M., Haase, C. M., Villeneuve, S., Vogel, J. W., & Jagust, W. J. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.02.015 · Cited by 138
Self-citationCerebral amyloid PET imaging in Alzheimer’s disease
Jack, C. R., Barrio, J. R., & Kepe, V. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1185-7 · Cited by 137
Self-citationYang, X., Yao, C., Tian, T., Li, X., Yan, H., Wu, J., Li, H., Pei, L., Liu, D., Tian, Q., et al. (2018) · Molecular Psychiatry · doi:10.1038/mp.2016.151 · Cited by 136
The role of egocentric and allocentric abilities in Alzheimer's disease: A systematic review
Serino, S., Cipresso, P., Morganti, F., & Riva, G. (2014) · Ageing Research Reviews · doi:10.1016/j.arr.2014.04.004 · Cited by 136
Injury markers predict time to dementia in subjects with MCI and amyloid pathology
van Rossum, I. A., Vos, S. J. B., Burns, L., Knol, D. L., Scheltens, P., Soininen, H., Wahlund, L.-O., Hampel, H., Tsolaki, M., Minthon, L., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e3182704056 · Cited by 136
Protective genes and pathways in Alzheimer’s disease: moving towards precision interventions
Seto, M., Weiner, R. L., Dumitrescu, L., & Hohman, T. J. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00452-5 · Cited by 135
Hertze, J., Minthon, L., Zetterberg, H., Vanmechelen, E., Blennow, K., & Hansson, O. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100207 · Cited by 135
The Lipoxygenases: Their Regulation and Implication in Alzheimer’s Disease
Czapski, G. A., Czubowicz, K., Strosznajder, J. B., & Strosznajder, R. P. (2015) · Neurochemical Research · doi:10.1007/s11064-015-1776-x · Cited by 137
Early Postmenopausal Transdermal 17β-Estradiol Therapy and Amyloid-β Deposition
Kantarci, K., Lowe, V. J., Lesnick, T. G., Tosakulwong, N., Bailey, K. R., Fields, J. A., Shuster, L. T., Zuk, S. M., Senjem, M. L., Mielke, M. M., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160258 · Cited by 135
Self-citationEvaluation of a Previously Suggested Plasma Biomarker Panel to Identify Alzheimer's Disease
Björkqvist, M., Ohlsson, M., Minthon, L., & Hansson, O. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029868 · Cited by 135
Cerebral perfusion in the predementia stages of Alzheimer’s disease
Binnewijzend, M. A. A., Benedictus, M. R., Kuijer, J. P. A., van der Flier, W. M., Teunissen, C. E., Prins, N. D., Wattjes, M. P., van Berckel, B. N. M., Scheltens, P., & Barkhof, F. (2015) · European Radiology · doi:10.1007/s00330-015-3834-9 · Cited by 134
Sabuncu, M. R., Buckner, R. L., Smoller, J. W., Lee, P. H., Fischl, B. R., & Sperling, R. A. (2011) · Cerebral Cortex · doi:10.1093/cercor/bhr348 · Cited by 134
Giorgio, J., Adams, J. N., Maass, A., Jagust, W. J., & Breakspear, M. (2024) · Neuron · doi:10.1016/j.neuron.2023.11.014 · Cited by 133
Self-citationChanges in Plasticity Across the Lifespan
Oberman, L. M., & Pascual‐Leone, Á. (2013) · Progress in brain research · doi:10.1016/b978-0-444-63327-9.00016-3 · Cited by 134
Darst, B. F., Koscik, R. L., Racine, A. M., Oh, J. M., Krause, R. A., Carlsson, C. M., Zetterberg, H., Blennow, K., Christian, B. T., Bendlin, B. B., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160195 · Cited by 133
Multi-method investigation of factors influencing amyloid onset and impairment in three cohorts
Betthauser, T. J., Bilgel, M., Koscik, R. L., Jedynak, B., An, Y., Kellett, K. A., Moghekar, A., Jonaitis, E. M., Stone, C. K., Engelman, C. D., et al. (2022) · Brain · doi:10.1093/brain/awac213 · Cited by 133
Nation, D. A., Edmonds, E. C., Bangen, K. J., Delano‐Wood, L., Scanlon, B. K., Han, S. D., Edland, S. D., Salmon, D. P., Galasko, D. R., & Bondi, M. W. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2014.4477 · Cited by 133
Within-patient correspondence of amyloid-β and intrinsic network connectivity in Alzheimer’s disease
Myers, N., Pasquini, L., Göttler, J., Grimmer, T., Koch, K., Ortner, M., Neitzel, J., Mühlau, M., Förster, S., Kurz, A., et al. (2014) · Brain · doi:10.1093/brain/awu103 · Cited by 132
Wagshal, D., Sankaranarayanan, S., Guss, V., Hall, T., Berisha, F., Lobach, I., Karydas, A., Voltarelli, L., Scherling, C., Heuer, H., et al. (2015) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-308004 · Cited by 132
Cerebral glucose metabolism and cognition in newly diagnosed Parkinson's disease: ICICLE-PD study
Firbank, M., Yarnall, A. J., Lawson, R. A., Duncan, G. W., Khoo, T. K., Petrides, G. S., O'Brien, J. T., Barker, R., Maxwell, R. J., Brooks, D. J., et al. (2016) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2016-313918 · Cited by 132
Farrell, M. E., Jiang, S., Schultz, A. P., Properzi, M. J., Price, J. C., Becker, J. A., Jacobs, H. I. L., Hanseeuw, B. J., Rentz, D. M., Villemagne, V. L., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000011214 · Cited by 132
NLRP3 inflammasome signalling in Alzheimer's disease
McManus, R. M., & Latz, E. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.109941 · Cited by 136
Entorhinal Cortex Thickness Predicts Cognitive Decline in Alzheimer's Disease
Velayudhan, L., Proitsi, P., Westman, E., Muehlboeck, J., Mecocci, P., Vellas, B. J., Tsolaki, M., Kłoszewska, I., Soininen, H. S., Spenger, C., et al. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-121408 · Cited by 132
When Does Alzheimer′s Disease Really Start? The Role of Biomarkers
Lloret, A., Esteve, D., Lloret, M.-A., Cervera-Ferri, A., Lopez, B., Nepomuceno, M., & Monllor, P. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225536 · Cited by 131
Trzepacz, P. T., Yu, P., Sun, J., Schuh, K. J., Case, M. G., Witte, M. M., Hochstetler, H. M., & Hake, A. M. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.06.018 · Cited by 131
Amyloid imaging as a biomarker for cerebral β-amyloidosis and risk prediction for Alzheimer dementia
Klunk, W. E. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.09.006 · Cited by 131
Jones, S. V., & Kounatidis, I. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01805 · Cited by 131
Liang, K. J., & Carlson, E. S. (2019) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2019.01.004 · Cited by 131
Iturria‐Medina, Y., Carbonell, F., Sotero, R. C., Chouinard-Decorte, F., & Evans, A. C. (2017) · NeuroImage · doi:10.1016/j.neuroimage.2017.02.058 · Cited by 130
Tsai, T., Lin, Y.-T., Hwang, B., Nakayama, S. F., Tsai, C., Sun, X., Ma, C., & Jung, C. (2019) · Environmental Research · doi:10.1016/j.envres.2019.108638 · Cited by 130
Scheltens, P., Hallikainen, M., Grimmer, T., Duning, T., Gouw, A. A., Teunissen, C. E., Wink, A. M., Maruff, P., Harrison, J., van Baal, C. M., et al. (2018) · Alzheimer's Research & Therapy · doi:10.1186/s13195-018-0431-6 · Cited by 129
Binnewijzend, M. A. A., Adriaanse, S. M., van der Flier, W. M., Teunissen, C. E., de Munck, J. C., Stam, C. J., Scheltens, P., van Berckel, B. N. M., Barkhof, F., & Wink, A. M. (2013) · Human Brain Mapping · doi:10.1002/hbm.22335 · Cited by 129
The aging brain and cognition: contribution of vascular injury and aβ to mild cognitive dysfunction
Marchant, N. L., Reed, B. R., Sanossian, N., Madison, C. M., Kriger, S., Dhada, R., Mack, W. J., DeCarli, C., Weiner, M. W., Mungas, D. M., et al. (2013) · JAMA Neurology · doi:10.1001/2013.jamaneurol.405 · Cited by 106
Self-citationRates of β-amyloid accumulation are independent of hippocampal neurodegeneration
Jack, C. R., Wiste, H. J., Knopman, D. S., Vemuri, P., Mielke, M. M., Weigand, S. D., Senjem, M. L., Gunter, J. L., Lowe, V. J., Gregg, B. E., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000386 · Cited by 129
Self-citationRokicki, J., Wolfers, T., Nordhøy, W., Tesli, N., Quintana, D. S., Alnæs, D., Richard, G., de Lange, A. G., Lund, M. J., Norbom, L. B., et al. (2020) · Human Brain Mapping · doi:10.1002/hbm.25323 · Cited by 129
RETRACTED: Soluble α-Synuclein Is a Novel Modulator of Alzheimer's Disease Pathophysiology
Larson, M. E., Sherman, M. A., Greimel, S., Kuskowski, M., Schneider, J. A., Bennett, D. A., & Lesné, S. E. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.0581-12.2012 · Cited by 128
RetractedCan we prevent Alzheimer's disease? Secondary “prevention” trials in Alzheimer's disease
Carrillo, M. C., Brashear, H. R., Logovinsky, V., Ryan, J. M., Feldman, H., Siemers, E., Abushakra, S. R., Hartley, D. M., Petersen, R. C., Khachaturian, A. S., et al. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.12.004 · Cited by 128
Self-citationKoelsch, G. (2017) · Molecules · doi:10.3390/molecules22101723 · Cited by 128
Hearing impairment is associated with cognitive decline, brain atrophy and tau pathology
Wang, H.-F., Zhang, W., Rolls, E. T., Li, Y., Wang, L., Ma, Y., Kang, J., Feng, J., Yu, J., & Cheng, W. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104336 · Cited by 128
Barone, E., Di Domenico, F., Mancuso, C., & Butterfield, D. A. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.09.018 · Cited by 127
Sperling, R. A., Johnson, K. A., Doraiswamy, P. M., Reiman, E. M., Fleisher, A., Sabbagh, M. N., Sadowsky, C., Carpenter, A. P., Davis, M. D., Lu, M., et al. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.06.014 · Cited by 127
Bernick, C. B., Banks, S. J., Shin, W., Obuchowski, N. A., Butler, S., Noback, M. N., Phillips, M., Lowe, M. J., Jones, S., & Modic, M. T. (2015) · British Journal of Sports Medicine · doi:10.1136/bjsports-2014-093877 · Cited by 127
Teter, B., Morihara, T., Lim, G. P., Chu, T., Jones, M. R., Zuo, X., Paul, R. M., Frautschy, S. A., & Cole, G. M. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.02.015 · Cited by 127
Obesity, leptin, and Alzheimer's disease
Lee, E. B. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.06274.x · Cited by 126
Utilizing the Centiloid scale in cross-sectional and longitudinal PiB PET studies
Su, Y., Flores, S., Hornbeck, R. C., Speidel, B., Vlassenko, A. G., Gordon, B. A., Koeppe, R. A., Klunk, W. E., Xiong, C., Morris, J. C., et al. (2018) · NeuroImage: Clinical · doi:10.1016/j.nicl.2018.04.022 · Cited by 126
Prediction of Conversion to Alzheimer’s Disease with Longitudinal Measures and Time-To-Event Data
Li, K., Chan, W., Doody, R. S., Quinn, J., Luo, S., & Initiative, T. A. D. N. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-161201 · Cited by 126
Kobayashi, Y., Kinoshita, T., Matsumoto, A., Yoshino, K., Saito, I., & Xiao, J. (2019) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2018.32 · Cited by 126
Weickenmeier, J., Jucker, M., Goriely, A., & Ellen Kuhl, A. (2018) · Journal of the Mechanics and Physics of Solids · doi:10.1016/j.jmps.2018.10.013 · Cited by 126
Natural product coumarins: biological and pharmacological perspectives
Hussain, M. I., Syed, Q. A., Khattak, M. N. K., Hafez, B., Reigosa, M. J., & El‐Keblawy, A. A. (2019) · Biologia · doi:10.2478/s11756-019-00242-x · Cited by 126
The Biological Functions and Signaling Mechanisms of the p75 Neurotrophin Receptor
Kraemer, B. R., Yoon, S. O., & Carter, B. D. (2014) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-45106-5_6 · Cited by 125
Yao, J., Rettberg, J. R., Klosinski, L. P., Cadenas, E., & Brinton, R. D. (2011) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2011.10.005 · Cited by 125
Schouten, T. M., Koini, M., de Vos, F., Seiler, S., van der Grond, J., Lechner, A., Hafkemeijer, A., Möller, C., Schmidt, R., de Rooij, M., et al. (2016) · NeuroImage Clinical · doi:10.1016/j.nicl.2016.01.002 · Cited by 125
A Mitocentric View of Alzheimer's Disease Suggests Multi-Faceted Treatments
Gibson, G. E., & Shi, Q. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-100336 · Cited by 124
Clinical and imaging features of mixed Alzheimer and vascular pathologies
Chui, H. C., & Ramirez-Gomez, L. (2015) · Alzheimer's Research & Therapy · doi:10.1186/s13195-015-0104-7 · Cited by 124
24S-hydroxycholesterol in plasma: A marker of cholesterol turnover in neurodegenerative diseases
Leoni, V., & Caccia, C. (2012) · Biochimie · doi:10.1016/j.biochi.2012.09.025 · Cited by 124
Is late‐onset Alzheimer's disease really a disease of midlife?
Ritchie, K. A., Ritchie, C. W., Yaffe, K. S., Skoog, I. G., & Scarmeas, N. (2015) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2015.06.004 · Cited by 124
Metadata
- Authors
- Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q.
- Affiliations
- Mayo Clinic (US)
- University of California, Berkeley (US)
- University of Pennsylvania (US)
- University of California San Diego (US)
- University of California, San Francisco (US)
- Corresponding author
- Jack, Clifford R
- ORCID
- Venue
- The Lancet Neurology
- Publisher
- Elsevier BV
- Published
- 2010-01
- Volume
- 9
- Issue
- 1
- Pages
- 119-128
- ISSN
- 1474-4422 (ISSN-L)
- PMC
- PMC2819840
- OpenAlex
- W2167840686
- Cited by
- 4,806
- References
- 119
- Citations by year
- 2026: 273 · 2025: 317 · 2024: 278 · 2023: 259 · 2022: 308 · 2021: 321 · 2020: 359 · 2019: 303 · 2018: 267 · 2017: 283 · 2016: 265 · 2015: 273 · 2014: 335 · 2013: 337 · 2012: 301
- FWCI
- 127.41
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Lancet Neurology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (AG11378)
- National Institute on Aging
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, amyloid-beta, amyloid PET, tau protein, brain atrophy, FDG-PET, synaptic dysfunction, neurodegeneration, disease stage, biomarkers, cognitive decline
- MeSH terms
- Aging, Alzheimer Disease, Brain, Cognition Disorders, Humans, Magnetic Resonance Imaging, Models, Neurological, Time Factors, Signal Transduction, Biomarkers, Amyloid beta-Peptides, tau Proteins, Disease Progression, Positron-Emission Tomography, Apolipoprotein E4, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
